drugset / Trial / NCT05736367
Investigating the Metabolic Pathways in Hormone Receptor Positive/HER2 Negative Breast Cancer
Recruiting
16 enrolled
Rutgers, The State University of New Jersey
Ludwig Institute for Cancer Research · collab
NaSingle-groupOpen-labelBasic science
Summary
To analyze the metabolic activity of Hormone Receptor Positive (HR+)/Her 2 Negative (Her2-) Breast cancer.
Timeline
- Start
- 2024-11-15
- Primary completion
- 2026-06-30
- Completion
- 2028-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | U-13C-glucose | Unknown | — | Intravenous |